These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 28529342)

  • 1. Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression.
    Skerenova M; Mikulova V; Capoun O; Zima T; Tesarova P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Sep; 161(3):272-280. PubMed ID: 28529342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?
    Darlix A; Lamy PJ; Lopez-Crapez E; Braccini AL; Firmin N; Romieu G; Thézenas S; Jacot W
    Int J Cancer; 2016 Nov; 139(10):2299-311. PubMed ID: 27464303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.
    Josefsson A; Linder A; Flondell Site D; Canesin G; Stiehm A; Anand A; Bjartell A; Damber JE; Welén K
    Prostate; 2017 Jun; 77(8):849-858. PubMed ID: 28295408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
    Lorente D; Olmos D; Mateo J; Dolling D; Bianchini D; Seed G; Flohr P; Crespo M; Figueiredo I; Miranda S; Scher HI; Terstappen LWMM; de Bono JS
    Ann Oncol; 2018 Jul; 29(7):1554-1560. PubMed ID: 29741566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
    Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
    Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
    BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer.
    Malani R; Fleisher M; Kumthekar P; Lin X; Omuro A; Groves MD; Lin NU; Melisko M; Lassman AB; Jeyapalan S; Seidman A; Skakodub A; Boire A; DeAngelis LM; Rosenblum M; Raizer J; Pentsova E
    J Neurooncol; 2020 Jul; 148(3):599-606. PubMed ID: 32506369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.
    Banys-Paluchowski M; Witzel I; Riethdorf S; Pantel K; Rack B; Janni W; Fasching PA; Aktas B; Kasimir-Bauer S; Hartkopf A; Solomayer EF; Fehm T; Müller V
    Breast Cancer Res Treat; 2018 Nov; 172(1):93-104. PubMed ID: 30003393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
    McDaniel AS; Ferraldeschi R; Krupa R; Landers M; Graf R; Louw J; Jendrisak A; Bales N; Marrinucci D; Zafeiriou Z; Flohr P; Sideris S; Crespo M; Figueiredo I; Mateo J; de Bono JS; Dittamore R; Tomlins SA; Attard G
    BJU Int; 2017 Nov; 120(5B):E30-E44. PubMed ID: 27539393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer.
    Marín-Aguilera M; Reig Ò; Lozano JJ; Jiménez N; García-Recio S; Erill N; Gaba L; Tagliapietra A; Ortega V; Carrera G; Colomer A; Gascón P; Mellado B
    Oncotarget; 2015 Apr; 6(12):10604-16. PubMed ID: 25871394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.
    Nagaya N; Nagata M; Lu Y; Kanayama M; Hou Q; Hotta ZU; China T; Kitamura K; Matsushita K; Isotani S; Muto S; Sakamoto Y; Horie S
    PLoS One; 2020; 15(1):e0226219. PubMed ID: 31986176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression.
    Patel S; Sumitra G; Koner BC; Saxena A
    Clin Biochem; 2011 Jul; 44(10-11):869-72. PubMed ID: 21565179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer.
    Yang YJ; Kong YY; Li GX; Wang Y; Ye DW; Dai B
    BJU Int; 2019 Aug; 124(2):258-267. PubMed ID: 30536520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-positive circulating tumor cells in breast cancer.
    Ignatiadis M; Rothé F; Chaboteaux C; Durbecq V; Rouas G; Criscitiello C; Metallo J; Kheddoumi N; Singhal SK; Michiels S; Veys I; Rossari J; Larsimont D; Carly B; Pestrin M; Bessi S; Buxant F; Liebens F; Piccart M; Sotiriou C
    PLoS One; 2011 Jan; 6(1):e15624. PubMed ID: 21264346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients.
    Danila DC; Samoila A; Patel C; Schreiber N; Herkal A; Anand A; Bastos D; Heller G; Fleisher M; Scher HI
    Cancer J; 2016; 22(5):315-320. PubMed ID: 27749322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer.
    Aurilio G; Sandri MT; Pruneri G; Zorzino L; Botteri E; Munzone E; Adamoli L; Facchi G; Cullurà D; Verri E; Rocca MC; Zurrida S; Iacovelli R; Nolè F
    Future Oncol; 2016 Sep; 12(17):2001-8. PubMed ID: 27255717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.
    Pierga JY; Hajage D; Bachelot T; Delaloge S; Brain E; Campone M; Diéras V; Rolland E; Mignot L; Mathiot C; Bidard FC
    Ann Oncol; 2012 Mar; 23(3):618-624. PubMed ID: 21642515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.